Cisplatin
Platinol · Platinum agent
Proximal tubular ATN + magnesium wasting; the archetype.
ATNLYTEPRE
SevereOpen →
Hydrazine alkylating agent
Procarbazine
Matulane · Procarb
A classic lymphoma alkylator listed among the cytotoxics with recognized renal complications.
ModerateHydrazine alkylating agent · approved 1969
Hodgkin lymphoma (MOPP and variants)Brain tumors (PCV regimen)
Signature kidney injury
Acute Tubular Necrosis
Not well quantified at the drug-specific level. Procarbazine appears in classic onconephrology reviews of the renal complications of cytotoxic therapy as an agent with recognized renal/urological complications, and it is part of multi-agent lymphoma regimens in which acute renal failure (often multifactorial — tumor lysis, volume depletion, combined nephrotoxins) is described. Discrete procarbazine-attributable nephrotoxicity is largely case-/review-level rather than quantified.
Source: Healy & Clarkson, Aust N Z J Med 1983 (renal complications of cytotoxic therapy)
Mechanism of kidney injury
As a hydrazine alkylator activated to reactive methylating and oxidizing intermediates (including hydrogen-peroxide generation), procarbazine can in principle injure renal tubular epithelium via alkylation and oxidative stress (an acute tubular pattern). Being an MAO inhibitor and a frequent hypersensitivity sensitizer, it can also contribute to a hypersensitivity/allergic acute interstitial nephritis pattern. In practice, kidney injury during procarbazine-containing regimens is usually multifactorial — tumor lysis, volume depletion, hypercalcemia, and co-administered nephrotoxins (cisplatin, methotrexate, nitrosoureas) — so isolating a pure procarbazine lesion is difficult and the published renal evidence is conservative and case-/review-based.
Clinical presentation
When implicated, a subacute creatinine rise; an ATN pattern would show granular casts and tubular proteinuria, whereas an interstitial/hypersensitivity pattern may accompany rash, fever, eosinophilia, and sterile pyuria. Hypersensitivity reactions to procarbazine are otherwise well recognized (pulmonary, dermatologic).
Onset
Variable; tumor-lysis-related AKI within days of starting in bulky disease, hypersensitivity-type injury after re-exposure.
Reversibility
Variable
Anticancer mechanism
Oral hydrazine-derivative alkylating agent that is metabolically activated (CYP- and oxidation-dependent) to reactive methyldiazonium species that methylate DNA and generate hydrogen peroxide, causing DNA strand breaks. A monoamine-oxidase inhibitor with dietary/drug interactions. Long-standing component of lymphoma regimens (MOPP) and brain-tumor therapy (PCV).
Management
Supportive: hydration, correct electrolytes and treat tumor lysis; hold the drug for significant AKI or hypersensitivity. For suspected interstitial nephritis, discontinue and consider corticosteroids with nephrology input. Within combination regimens, identify and address the dominant contributor.
Risk factors
- Bulky/chemosensitive disease (tumor lysis)
- Concurrent nephrotoxins in combination regimens (cisplatin, methotrexate, nitrosoureas)
- Volume depletion
- Prior hypersensitivity to procarbazine
Prevention
- Tumor-lysis prophylaxis (hydration, urate-lowering) in high-burden disease
- Maintain hydration and avoid additive nephrotoxins where possible
- Recognize and avoid re-challenge after hypersensitivity
- Monitor renal function during combination therapy
Note · Renal-specific literature is thin and historical; kidney injury in procarbazine regimens is typically multifactorial. Classification here (ATN signature with possible hypersensitivity interstitial nephritis) is conservative and class-/case-based rather than quantified.
Clinical depth
Renal dose adjustment
No well-validated renal dosing algorithm; use caution in renal impairment given active metabolite handling, and consider dose reduction with close monitoring. Hepatic impairment and MAO-inhibitor drug/dietary interactions are the better-defined dosing concerns.
Dialyzability & ESKD dosing
Dialyzability not well characterized; the parent drug is short-lived and extensively metabolized. No established ESKD dosing — manage clinically with attention to active metabolites.
Differential diagnosis
In a procarbazine regimen, separate tumor-lysis AKI, prerenal volume depletion, and co-administered platinum/methotrexate/nitrosourea nephrotoxicity from a drug-specific tubular or hypersensitivity interstitial lesion; rash/fever/eosinophilia and sterile pyuria point to interstitial nephritis.
Monitoring
- Serum creatinine/eGFR during therapy
- Tumor-lysis labs (potassium, phosphate, uric acid, calcium) in bulky disease
- Urinalysis if creatinine rises (casts vs pyuria/eosinophiluria)
- Signs of hypersensitivity (rash, fever, eosinophilia)
Key trials & series
- Healy & Clarkson Aust N Z J Med 1983 cytotoxic renal-complications review (lists procarbazine)
- Historical MOPP and PCV regimen experience
Clinical pearls
- AKI during a procarbazine-containing regimen is usually multifactorial — look for tumor lysis, volume depletion, and partner nephrotoxins before blaming procarbazine.
- Procarbazine is a recognized hypersensitivity sensitizer; rash/fever/eosinophilia with a creatinine rise suggests interstitial nephritis — stop and consider steroids.
- It is an MAO inhibitor — the dominant safety teaching is dietary/drug interactions, with renal injury a secondary, conservative concern.
- Give tumor-lysis prophylaxis in bulky lymphoma where procarbazine regimens are used.
Where it strikes
Nephron segments
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Interstitium
Supporting tissue around the tubules
Injury signatures
Acute Tubular NecrosisAcute Interstitial Nephritis
Beyond the kidney
Class-level context for the major non-renal toxicities of hydrazine alkylating agents.
Ophthalmic
Keratopathy, uveitis, retinopathy
- Visual disturbance (crizotinib)
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Transaminitis
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- CNS effects (lorlatinib)
Evidence
4 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkRenal complications of cytotoxic therapy.Healy HG et al. · Aust N Z J Med 1983 · PMID 6228218Classic review of cytotoxic-drug renal complications listing procarbazine among agents with recognized renal/urological toxicity.PMIDLong-term survival of patients with multiple myeloma and acute renal failure at presentation.Lazarus HM et al. · Am J Kidney Dis 1983 · PMID 6402926Context for acute renal failure during procarbazine-containing combination chemotherapy regimens.PMIDAcute Kidney Injury in Patients with Cancer.Rosner MH et al. · N Engl J Med 2017 · PMID 28467867Authoritative review of cancer-associated AKI including tumor lysis, hypersensitivity interstitial nephritis, and combination-regimen nephrotoxicity.PMIDConventional Chemotherapy Nephrotoxicity.Gupta S et al. · Adv Chronic Kidney Dis 2021 · PMID 35190107Onconephrology reference framing alkylator and combination-chemotherapy renal injury and electrolyte disturbance.